» Articles » PMID: 4007028

Decreased Renal Clearance of Digoxin in Chronic Congestive Heart Failure

Overview
Specialty Pharmacology
Date 1985 Jan 1
PMID 4007028
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Renal digoxin clearance was compared in patients suffering from atrial fibrillation with well preserved cardiac function (n = 9; salt intake +/- 170 mmol daily) and patients with chronic congestive heart failure (n = 10; salt intake 50 mmol daily and maintenance treatment with diuretics). There was no difference between the groups concerning digoxin dosage, creatinine clearance, diuresis or sodium excretion in the urine. Digoxin clearance in chronic heart failure proved to be significantly lower than in atrial fibrillation (48 +/- 21 vs 71 +/- 36 ml X min-1, p less than 0.05), and Cdig/Ccreat was similarly reduced at 0.73 +/- 0.15 compared to 1.09 +/- 0.27 (p less than 0.005). Steady state serum digoxin concentration was significantly higher in patients with congestive heart failure (1.44 +/- 0.47 vs 0.87 +/- 0.33 micrograms X 1(-1), p less than 0.01). Chronic congestive heart failure is a state with reduced digoxin clearance by the kidney, which could lead to digoxin intoxication not explicable by overdose, reduced renal function or the effect of interacting drugs.

Citing Articles

Population pharmacokinetic analysis and dosage recommendations for digoxin in Japanese patients with atrial fibrillation and heart failure using real-world data.

Hirai T, Kasai H, Naganuma M, Hagiwara N, Shiga T BMC Pharmacol Toxicol. 2022; 23(1):14.

PMID: 35144695 PMC: 8830040. DOI: 10.1186/s40360-022-00552-y.


Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review.

Jalil M, Abdullah N, Alsous M, Abu-Hammour K Eur J Drug Metab Pharmacokinet. 2021; 46(3):325-342.

PMID: 33616855 DOI: 10.1007/s13318-021-00672-6.


A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population.

Abdel Jalil M, Abdullah N, Alsous M, Saleh M, Abu-Hammour K Br J Clin Pharmacol. 2020; 86(7):1267-1280.

PMID: 32153059 PMC: 7667574. DOI: 10.1111/bcp.14272.


The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Mangoni A, Jarmuzewska E Br J Clin Pharmacol. 2018; 85(1):20-36.

PMID: 30194701 PMC: 6303202. DOI: 10.1111/bcp.13760.


Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Ogawa R, Stachnik J, Echizen H Clin Pharmacokinet. 2014; 53(12):1083-114.

PMID: 25248847 DOI: 10.1007/s40262-014-0189-3.


References
1.
Mungall D, Robichaux R, Perry W, Scott J, Robinson A, Burelle T . Effects of quinidine on serum digoxin concentration: a prospective study. Ann Intern Med. 1980; 93(5):689-93. DOI: 10.7326/0003-4819-93-5-689. View

2.
Waldorff S, Andersen J, NIELSEN O, MOLTKE E, Sorensen U, Steiness E . Spironolactone-induced changes in digoxin kinetics. Clin Pharmacol Ther. 1978; 24(2):162-7. DOI: 10.1002/cpt1978242162. View

3.
Lindenbaum J, Maulitz R, Butler Jr V . Inhibition of digoxin absorption by neomycin. Gastroenterology. 1976; 71(3):399-404. View

4.
Steiness E . Renal tubular secretion of digoxin. Circulation. 1974; 50(1):103-7. DOI: 10.1161/01.cir.50.1.103. View

5.
Gibson T, Quintanilla A . Effect of volume expansion and furosemide diuresis on the renal clearance of digoxin. J Pharmacol Exp Ther. 1981; 219(1):54-9. View